MD Anderson registers Phase 2 trial of Summit's ivonescimab in rare adrenal cancers
A new Phase 2 study testing ivonescimab in adrenocortical carcinoma and pheochromocytoma/paraganglioma was registered, with Summit Therapeutics as collaborator.
This week's activity centers on a single newly registered trial involving Summit Therapeutics as a study collaborator.
- A Phase 2 trial called "STOMP OUT" will test whether ivonescimab can help control previously treated, locally advanced or metastatic ACC or PPGL.1 The study is sponsored by M.D. Anderson Cancer Center, with Summit Therapeutics as a collaborator.1 It is not yet recruiting, with an estimated start date of 2027-02-07.1 The trial plans to enroll 20 participants (estimated)1 and its primary objective is to estimate objective response rate (ORR) in both arms.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.